protocol_id stringclasses 263
values | section_number stringlengths 1 12 | title stringlengths 1 1.88k | content stringlengths 0 866k | merged_titles listlengths 0 491 |
|---|---|---|---|---|
NCT05673889 | 10.9 | Appendix 9: Overview of GLP Safety Pharmacology and Toxicology Testing Program for ARV-471 (PF-07850327) | 10.9. Appendix 9: Overview of GLP Safety Pharmacology and Toxicology Testing Program for ARV-471 (PF-07850327) Table 7. Overview of GLP Safety Pharmacology and Toxicology Testing Program for ARV-471 (PF-07850327) | Study Number(SponsorReferencea) | Study Title | Test Facility in Whichthe Study WasConducted | Date Range... | [] |
NCT05673889 | 10.10 | Appendix 10: Abbreviations | 10.10. Appendix 10: Abbreviations The following is a list of abbreviations that may be used in the protocol. | Abbreviation | Term | |--------------|--------------------------------------------------------------------------------------------------------------------------------------| | Abs | absolute | | ADL | activity... | [] |
NCT05673889 | 11 | REFERENCES | 11. REFERENCES - 1 FDA Guidance for Industry. In vitro drug interaction studies – Cytochrome P450 enzyme- and transporter-mediated drug interactions. January 2020. Available from: https:/[/www.fda.gov/regulatory-information/search-fda-guidance-documents/vitro-drug](http://www.fda.gov/regulatory-information/search-fda-g... | [
"4 CCI"
] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.